Adicet Bio, Inc. (ACET)
Healthcare
- Fundamental
- 3
- Sentiment
- 4
- Technical
- 4
Do Nothing: liquidity hard blocks — avgDollarVolume20 $830,930.51 is far below the $5,000,000 floor and the recent 3-session regular-session average $703,737 is below the $1,500,000 recent-liquidity floor; the chart is strong (technicalScore 4) but the tape is too thin to swing-trade.
Company overview
Adicet Bio, Inc. is a biotechnology company focused on developing allogeneic gamma delta T cell therapies to treat cancer and other diseases. The firm engineers gamma delta T cells with chimeric antigen receptors and T cell receptor-like antibodies for precise tumor targeting. Its leading candidate, ADI-001, is in a Phase I trial for non-Hodgkin's lymphoma, while ADI-002 is in preclinical stages for solid tumors.
Fundamental
fairAdicet Bio shows strong liquidity but faces ongoing losses and dilution risks, typical of clinical-stage biotech firms.
Clinical-stage biotech with $0 revenue and ongoing losses, but a strong liquidity position: ~$118.2M of cash/cash equivalents/short-term investments at 2026-06-30 and a high current ratio, with management indicating runway into the back half of 2027. The investment case is fundamentally a clinical-data and future-dilution bet rather than an earnings or multiple-driven story.
Sentiment
goodPositive sentiment driven by FDA clearance and institutional interest, despite sparse retail activity.
An announced, still-unpriced FDA IND clearance for ADI-212 (2026-08-27) heads a bullish catalyst stack that also carries RA Capital's new 9.99% stake and a prula-cel lupus nephritis readout guided for Q3 2026, against mildly positive in-window media sentiment (aggregate ≈ +0.12) and an indeterminate sentiment delta (sparse analyzer baseline). Red-Flag Screen clean.
Technical
goodThe stock is in an uptrend with positive technical indicators, but low liquidity prevents actionable trades.
Score 4 of 5: price sits above SMA20/50/200 and EMA9/21 in a rising ADX14 (40.67) up-trend, MACD line 0.16 is above signal 0.14 and above zero, and the 2026-08-27 session printed roughly 3x average volume on the FDA IND clearance for ADI-212; the one weak signal is neutral momentum depth (RSI14 54.99, Williams %R -35.56, price just below WMA9/DEMA14). The action is still Do Nothing because the tape fails both liquidity floors (20-day average dollar volume ~$831K vs the $5M floor; recent 3-session regular-session average ~$704K vs the $1.5M recent-liquidity floor), so setupType is forced to no_setup regardless of chart quality.
You’re looking at 2026-08-27 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.